The Acute Effects of Monoamine Reuptake Inhibitors on the Stimulus Effects of
Hallucinogens
J. C. Winter
, a,
Scott Helsleya,
David Fiorellaa
and R. A. Rabina
a Department of Pharmacology and
Toxicology, School of Medicine and Biomedical Sciences, State University of New
York at Buffalo, 102 Farber Hall, Buffalo, NY 14214-3000 USA
Received 15
May 1998; revised 22 December 1998; accepted 11 January 1999. Available online
25 June 1999.
Abstract
In a previous study it was observed that fluoxetine potentiates the stimulus
effects of lysergic acid diethylamide (LSD). In the present investigation,
stimulus control was established in groups of rats using as training drugs the
hallucinogens lysergic acid diethylamide (LSD); 0.1 mg/kg),
(-)-2,5-dimethoxy-4-methylamphetamine [(-)-DOM; 0.56 mg/kg], ibogaine (10
mg/kg), and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT; 3 mg/kg). A
two-lever, fixed-ratio 10, positively reinforced task with saline controls was
employed. The hypotheses tested were that (a) monoamine uptake inhibitors other
than fluoxetine potentiate the discriminative effects of LSD, and (b)
hallucinogens other than LSD are potentiated by acute pretreatment with
monoamine uptake inhibitors. The effects of a range of doses of each of the
training drugs were determined both alone and following pretreatment with the
monoamine reuptake inhibitors fluoxetine, fluvoxamine, and venlafaxine. In
LSD-trained subjects, all three reuptake inhibitors caused a significant
increase in LSD-appropriate responding. Similar results were observed in rats
trained with (-)-DOM and with ibogaine. In 5-MeO-DMT–trained subjects, only
fluoxetine resulted in an enhancement of drug-appropriate responding. The
reuptake inhibitors given alone elicited varying degrees of responses
appropriate for the respective training drugs. For fluoxetine in rats trained
with LSD and ibogaine, for venlafaxine in LSD trained, and for fluvoxamine in
(-)-DOM trained, the degree of responding met our criterion for intermediate
responding, i.e., significantly different from both training conditions.
Subsequent experiments in (-)-DOM–trained subjects examined a range of doses of
each of the reuptake inhibitors in combination with a fixed dose of ( -)-DOM
(0.1 mg/kg), which alone yielded about 50% (-)-DOM–appropriate responding. With
the exception of the point obtained with the highest dose of venlafaxine, all
data were compatible with additivity of effects rather than true potentiation.
In summary, the present data extend our previous observation of the augmentation
of the stimulus effects of LSD by fluoxetine to include other hallucinogens. The
mechanisms by which these interactions arise and possible differential effects
of acute and chronic treatment remain to be established.
Author Keywords: Drug discrimination; Rat; SSRIs;
Hallucinogens; DOM; LSD; Ibogaine
Index Terms: drug discrimination; reinforcement; psychedelic
agent
Requests for reprints
should be addressed to Dr. J. C. Winter, State University of New York at
Buffalo, Department of Pharmacology and Toxicology, School of Medicine &
Biomedical Sciences, 102 Farber Hall, Buffalo, NY 10566-3000